Last reviewed · How we verify
L-DEP and PD-1 antibody
L-DEP and PD-1 antibody is a PD-1 inhibitor combination therapy Small molecule drug developed by Beijing Friendship Hospital. It is currently in Phase 3 development for Advanced or metastatic solid tumors (specific indication under investigation in phase 3).
L-DEP and PD-1 antibody is a combination therapy that enhances anti-tumor immunity by blocking PD-1 checkpoint inhibition while L-DEP provides immunomodulatory support.
L-DEP and PD-1 antibody is a combination therapy that enhances anti-tumor immunity by blocking PD-1 checkpoint inhibition while L-DEP provides immunomodulatory support. Used for Advanced or metastatic solid tumors (specific indication under investigation in phase 3).
At a glance
| Generic name | L-DEP and PD-1 antibody |
|---|---|
| Sponsor | Beijing Friendship Hospital |
| Drug class | PD-1 inhibitor combination therapy |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The PD-1 antibody component blocks the programmed death-1 checkpoint, releasing T-cell exhaustion and restoring anti-tumor immune responses. L-DEP (likely a derivative or immunomodulatory agent) works synergistically to enhance immune activation and tumor recognition. This combination approach aims to improve efficacy in checkpoint-resistant or difficult-to-treat malignancies.
Approved indications
- Advanced or metastatic solid tumors (specific indication under investigation in phase 3)
Common side effects
- Immune-related adverse events (irAEs)
- Fatigue
- Diarrhea
- Pneumonitis
- Hepatotoxicity
Key clinical trials
- L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH (PHASE3)
- L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-DEP and PD-1 antibody CI brief — competitive landscape report
- L-DEP and PD-1 antibody updates RSS · CI watch RSS
- Beijing Friendship Hospital portfolio CI
Frequently asked questions about L-DEP and PD-1 antibody
What is L-DEP and PD-1 antibody?
How does L-DEP and PD-1 antibody work?
What is L-DEP and PD-1 antibody used for?
Who makes L-DEP and PD-1 antibody?
What drug class is L-DEP and PD-1 antibody in?
What development phase is L-DEP and PD-1 antibody in?
What are the side effects of L-DEP and PD-1 antibody?
What does L-DEP and PD-1 antibody target?
Related
- Drug class: All PD-1 inhibitor combination therapy drugs
- Target: All drugs targeting PD-1
- Manufacturer: Beijing Friendship Hospital — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced or metastatic solid tumors (specific indication under investigation in phase 3)
- Compare: L-DEP and PD-1 antibody vs similar drugs
- Pricing: L-DEP and PD-1 antibody cost, discount & access